Related Experiment Videos
[Studies on the recurrent trophoblastic disease].
Nihon Sanka Fujinka Gakkai Zasshi
|October 1, 1982
Summary
This study on trophoblastic disease found high remission rates but noted recurrence risks, especially in high-risk cases. Monitoring human chorionic gonadotropin-beta levels for three months is crucial for remission criteria in high-risk patients.
Area of Science:
- Gynecology
- Oncology
- Reproductive Endocrinology
Context:
- Trophoblastic disease management requires understanding remission and recurrence patterns.
- Historical data from 1973-1980 provides insights into treatment outcomes.
- Analysis of 168 cases highlights varying risk factors.
Purpose:
- To evaluate remission and recurrence rates of trophoblastic disease.
- To identify prognostic factors influencing disease outcomes.
- To establish criteria for remission in high-risk patients.
Summary:
- Overall remission rate was 91.1% (153/168) with a 5.2% (8/153) recurrence rate.
- High-risk cases showed a 65.9% remission and 20.7% recurrence rate, contrasting with 100% remission and 1.6% recurrence in low-risk cases.
- Recurrence occurred within a year in 5 cases and over a year in 3 cases.
- Human chorionic gonadotropin-beta (hCG-beta) titers below luteinizing hormone (LH) levels for three months are proposed as a remission criterion for high-risk patients.
- Chemotherapy regimens were adjusted based on hCG-beta titers, with >1.0 ng/mL necessitating further treatment.
Impact:
- Informs clinical decision-making for trophoblastic disease treatment.
- Suggests refined remission criteria for high-risk patient populations.
- Highlights the importance of serial hCG-beta monitoring in managing trophoblastic neoplasia.